Comparative healthcare costs in patients with metastatic melanoma in the USA.
2015
Recent advances have increased treatment options for, and improved clinical outcomes in, metastatic melanoma (mM). Using a large claims database, this retrospective study compared healthcare and adverse event (AE) costs in a US managed care population of mM patients initiating vemurafenib (VEM), ipi
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
28
References
18
Citations
NaN
KQI